(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)'s sale to Biogen Inc. for $172.50 per share in cash. If you are a Reata shareholder, click here to learn more about your rights and options .
EQRx, Inc. (NASDAQ: EQRX)'s merger with Revolution Medicines, Inc. If you are an EQRx shareholder, click here to learn more about your rights and options .
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)'s sale to SoftBank Group Corp. and its affiliate for $1.40 per share. If you are a Berkshire shareholder, click here to learn more about your rights and options .
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email or .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
Tags class action
MENAFN03082023004107003653ID1106778024
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.